

Full Length Research Paper

# Cloning and expression of *Corynebacterium diphtheriae* toxin gene

Nsrin Mohammadi<sup>1</sup>, Mojgan Bandehpour<sup>2</sup>, Fatemeh Yarian<sup>2</sup>, Parvi Pakzad<sup>1</sup>, Bahram Kazemi<sup>2&3</sup>, Mehdi Besharat<sup>4\*</sup>

<sup>1</sup>Islamic Azad University, Tehran North branch, Tehran, Iran.

<sup>2</sup>Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>3</sup>Biotechnology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>4</sup>Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Accepted 23 August, 2011

Diphtheria is an acute bacterial disease caused by oxygenic strains of *Corynebacteria*. Fatality rate of this disease, between 5 and 10%. In children under 5 years and adults, the fatality rate may be as much as 20%. Outbreaks, although very rare, still occur worldwide, even in developed nations. Diphtheria toxin (DT) is the major virulence factor for these organisms. The aim of this study was cloning and expression diphtheria toxin gene to produce recombinant protein and application in next investigations. The bacterial DNA was extracted and amplification of diphtheria toxin gene was carried out with specific primers. This gene was cloned in pTZ57R/T vector and sub cloned into pETDuet-1 expression vector then recombinant plasmid was transformed into BL21 of *Escherichia coli* strain and induced by IPTG. Diphtheria toxin gene was amplified successfully and cloned in pTZ57R. Recombinant plasmid was digested by restriction enzymes and released fragment (diphtheria toxin gene) sub cloned in pETDuet-1 expression vector and expressed protein was analysed in serological assay. In this study, the diphtheria toxin gene was cloned in pETDuet-1 expression vector and confirmed by sequencing and restriction analysis then recombinant plasmid was transformed in BL21 expression cell.

**Key words:** Diphtheria, *Corynebacterium diphtheriae* toxin gene, recombinant protein, pETDuet-1.

## INTRODUCTION

Diphtheria is a highly infectious disease caused by *Corynebacterium diphtheriae*, an aerobic, gram-positive, nonsporulating bacterium. Fatality rate of this disease is between 5 and 10%. In children under 5 years and adults, the fatality rate may be as much as 20%. Outbreaks, although very rare, still occur worldwide, even in developed nations (Todar, 2008). The disease is usually transmitted by droplet contact. This is an upper respiratory tract illness characterized by sore throat, low fever, and an adherent membrane (called a pseudomembrane) on the tonsils, pharynx, and nasal cavity. Diphtheria toxin produced by *C. diphtheriae*, can cause myocarditis, polyneuritis, and other systemic toxic effects. A milder form of diphtheria can be restricted to the skin. The

virulence factor of *C. diphtheriae* is diphtheria toxin (DT), a highly toxic protein expressed after infection by a specific toxin+ corynebacteriophage (Bachran et al., 2007; Brooks et al., 2007). After treatment with trypsin and reducing agents, toxin (molecular weight 62 kDa) can be dissociated into two polypeptides, fragment A (21,145 kDa) and fragment B (38 kDa) (DeLange et al., 1976; Drazin et al., 1971; Gill and Dinis., 1971). Fragment A, the amino-terminal region of the toxin molecule, is an enzyme that catalyzes transfer of the adenosine diphosphateribose (ADP-ribosylation) moiety from nicotinamide adenine dinucleotide to eukaryotic elongation factor 2 (EF-2), thereby inactivating EF-2 and inhibiting protein synthesis in eucaryotic cells, and caused cell death (Collier and Kandel, 1971; Gill and Pappenheimer, 1971; Honjo et al., 1968). Fragment B, the carboxy-terminal portion of the toxin molecule is essential for the binding of toxin to specific receptors on the plasma membrane of susceptible eucaryotic cells, consists of two separate protein folding domains; the R-

\*Corresponding author. E-mail: Tel/Fax: +9821 22439956;  
Email: [m\\_besharat@live.com](mailto:m_besharat@live.com)

domain that binds to the cell surface receptor and the T-domain that can insert into membranes and mediate translocation of the A-fragment across the membrane (Naglich et al., 1992; Ittelson and Gill., 1973; Uchida et al., 1973). Diphtheria toxin bound to its receptor is endocytosed by clathrin-dependent endocytosis. When the toxin encounters the acidic pH in the endosomes, a conformational change occurs and a double helix in the T-domain inserts into the endosomal membrane. The membrane-inserted hairpin assists the A-fragment to translocate across the endosomal membrane, and after reduction of the disulfide bridge the A-fragment is released in the cytosol (Papini et al., 1993). The aim of this study was cloning and expression diphtheria toxin gene to produce recombinant protein and application in next investigations.

## MATERIALS AND METHODS

### Bacterial DNA and plasmids

*C. diphtheriae* DNA was gift from Razi Vaccine and Serum Research Institute. The pETDuet-1 and pTZ57R plasmids were purchased from Novagen Company.

### Gene cloning

A pair of primer was designed based on Diphtheria toxin gene sequence: forward and reverse F- 5'-GGA TCC ATG GGC GCT GAT GAT GTT G-3' R- 5'-GAA TTC TCA GCT TTT GAT TTC AAA AAA TAG CG-3' with *EcoRI* and *BamHI* restriction enzymes site at 5' end of forward and reverse primers respectively. The DNA of *C. diphtheriae* was extracted and Diphtheria toxin gene was amplified via PCR reaction and PCR product was submitted to electrophoresis using 1/5% agarose gel, then stained by sybergreen and submitted for sequencing by dideoxy chain termination method. Amplified fragment was cloned in pTZ57R plasmid by T/A cloning as reported previously (Gaastra and Hansen., 1984). Contents of reaction were transfer into *E. coli*, Top10 strain competent cell (Hanahan, 1983). Then product of reaction was dispensed on LB (Luria-Bertani) agar plate containing ampicillin (50 mg/mL), Xgal (20 mM) and IPTG (200 mg/ml). White colonies containing recombinant plasmid was selected and extracted (Felicicello and Chinali., 1993). Released DNA (dt gene) was sub cloned in *BamHI* and *EcoRI* digested pETDuet-1 expression vector and digested by BamHI and *EcoRI* restriction enzymes.

The released fragment DNA (dt gene) was ligated into *BamHI* and *EcoRI* digested pETDuet-1 expression vector and Recombinant plasmid was confirmed by both specific PCR and enzyme digestion methods.

### Gene expression

The *E. coli* strain BL21 was transformed with recombinant plasmid and selected on LB agar containing 50 µg/ml of ampicillin and incubated at 37°C in a shaker at 200 rpm overnight (Sorensen and Mortensen, 2005; Baneyx, 1999). The following day, the cultured bacteria was inoculated into 50 ml X medium (1.2% bacto trypton, 2.4% yeast extract, 0.04% glycerol, 1% M9 salts) (M9 salts contain: 6.4% Na<sub>2</sub>H<sub>2</sub>O<sub>4</sub>-7H<sub>2</sub>O, 1.5% KH<sub>2</sub>PO<sub>4</sub>, 0.025% NaCl, 0.05%

NH<sub>4</sub>CL) and was allowed to grow at 37°C in a shaker at 200 rpm for 2 h. When the cultures were in logarithmic phase (at OD<sub>600</sub> of 0.6), the porometer gene was induced for different hours with 1mM isopropyl β- D-thiogalactopyranoside (IPTG). After induction, cells were lysed in 5x sample buffer (100 mM Tris HCL Ph 8.20% glycerol, 4% SDS, 2% beta mercapto-ethanol, 0.2% bromophenol blue) and analyzed by 10% SDS-polyacrylamide gel (Baneyx, 1999; Smith, 1984a). The gel was stained by coomassie brilliant blue R- 250 (Smith, 1984b). Uninduced control culture was analyzed in parallel.

### Serological assay

#### Immuno diffusion

Gel diffusion was done using induced lysate cells as antigen and horse anti toxin serum as antibody loaded on 1% agarose gel in phosphate buffered saline (PBS) and incubated over night at 37°C (Hudson and Hay, 1998).

#### Dot blot analysis

Lysate-induced cells were blotted on nitrocellulose membrane. Nitrocellulose membrane blot was reacted by primary antibody (horse anti toxin serum) and then by secondary antibody (rabbit anti- horse IgG peroxidase conjugated), and subsequently detected by its substrate (Shewry and Fido, 1998).


#### Western blot analysis

Protein resolved by SDS-PAGE was electrophoretically transferred to a nitrocellulose membrane. The membran was incubated in TBS (Tris-Buffered Saline containing 3% BSA (Bovine Serum Albumin) and then washed several times. Membrane was then incubated with a 1:200 dilution of primary antibody (horse anti toxin serum) in a shaker at 70 rpm for 2 h. Then washed several times by TBS and TBST (TBS-Tween 20) subsequently treated with a 1:200 dilution horseradish peroxidase (HRP) rabbit anti- horse IgG peroxidase conjugated in a shaker at 70 rpm for 2 h. Afterwards washing several times, the strips were visualized for color after development in Di Amino Benzidine/H<sub>2</sub>O<sub>2</sub> substrate solution for 15 min at room temperature. The reaction was stopped by washing four times in distilled water (Sambrook and Russell, 2001).


## RESULTS

*C. diphtheriae* toxin gene was amplified from extracted DNA of bacteria by using specific forward and reversed primers. Figure 1 shows 1611 bp as PCR product that it was electrophoresed on 1.5% agarose gel in parallel with 100 bp DNA ladder size marker.


The PCR product was ligated in pTZ57R T-vector and transformed into *E. coli* Top10 strain. Recombinant plasmid was extracted and digested with *BamHI* and *EcoRI* restriction enzymes (Figure 2). Also recombinant plasmid was confirmed by PCR with specific primers (Figure 3). Release DNA band was purified by DNA purification kit and subcloned in *BamHI* and *EcoRI* digested pETDuet-1 expression vector Figure 4 shows supercoil no recombinant plasmid and digested recombinant plasmid. Confirmation of the plasmid was




**Figure 1.** Electrophoresis of PCR on 1.5% agarose gel. Line 1: The 1611 bp as PCR product of *dt* gene. Line 2: 100 bp DNA ladder marker.



**Figure 3.** Electrophoresis of PCR on 1.5% agarose gel. Line 1: Confirming cloned gene in pTZ57R T/vector (using specific primer for *dt* gene). Line 2: 100-bp DNA ladder marker.



**Figure 2.** Electrophoresis on 1% agarose gel. Lane 1: 100 bp DNA ladder marker, Lane 2: not digested pTZ57R/dt, Lane 3: Digested pTZ57R/dt by *Bam*HI & *Eco*RI.



**Figure 4.** Electrophoresis on 1% agarose gel. Lane 1: not digested pETDuet-1/dt, Lane 2: Digested pETDuet-1/dt by *Bam*HI & *Eco*RI, Lane 3: 100 bp DNA ladder marker

also showed by PCR (Figure 5).


Figure 6 shows SDS-polyacrylamide gel electrophoresis loaded by interval sampling 3 and 5 hours after induction by IPTG. The induced protein is approximately 60 kDa, parallel with the protein size marker.

Dot blot was used with 1/100, 1/250, 1/500 diluted horse anti toxin serum as antibody and 1/200 diluted lysate induced cells as antigen. Figure 7 shows the dot


blot analysis detected after the enzyme – substrate reaction.

Arc produced in gel diffusion test by antibody- antigen reaction, was seen using induced lysate cells as antigen and DT-infected serum as antibody (Figure 8).


Western blot analyse confirmed the protein with approximately 60 kDa strip as recombinant protein that




**Figure 5.** Electrophoresis of PCR on 1.5% agarose gel. Line 1: 100 bp DNA ladder marker. Line 2: Confirming sub cloning *dt* gene in pETDuet-1, expression vector (using specific primer for *dt* gene).



**Figure 6.** SDS-polyacrylamide gel electro-phoresis. Line 1: protein marker. Line 2: Lysate of BL21 cell without recombinant DT protein. Line 3: Lysate of BL21 containing recombinant DT protein, collected 3h after induction. Line 4: Lysate of BL21 containing recombinant DT collected 5h after induction.



**Figure 7.** Dot blot analysis by 1:100, 1:250 and 1:500 diluted DT-anti toxin serum and detected by rabbit anti- horse IgG peroxidase conjugated.



**Figure 8.** Immuno diffusion analysis by 1, 1:10 and 1:100 diluted DT anti toxin serum, p: Lysate of BL21 containing recombinant DT, collected 3 h after induction s: negative serum.



**Figure 9.** Immunoblotting. Line 1: Cell lysates without recombinant DT, Line 2: Cell lysates containing recombinant DT 3h after induction (expression).

was transferred to nitrocellulose membrane (Figure 9).

## DISCUSSION

Diphtheria was one of the most important causes of death in the first half of the twentieth century (Skogen et al., 2000). The exotoxin of toxigenic strains of *C. diphtheriae* is responsible for local and systemic toxicity seen during diphtheria (Mandell and Dolin, 1995). Immunity to diphtheria is mainly provided by IgG antibodies made against the exotoxin, which is a powerful antigen (Bigio et al., 1987). Some epidemiological studies were carried out by this antigen (Holmes, 2000) and some studies were used this antigen for vaccination (Lobeck et al., 1998). Others used this antigen for diagnostic (Aybay and Yücel., 2003 Nakao and Popovic, 1997; Mikhailovich et al., 1995). In 1909, Smith proposed that nontoxic mixtures of DT and diphtheria antitoxin at equivalence could be used for active immunization of humans against diphtheria. A successful large-scale trial of toxin-antitoxin vaccine was conducted in 1922. Ramon in 1923 discovered that treatment with formalin eliminated the toxicity of DT without destroying its immunogenicity. Formalin-treated DT, now called diphtheria toxoid, Diphtheria toxoid usually in combined vaccines, such as diphtheria-tetanus toxoids– pertussis vaccine [DTP] or diphtheria-tetanus toxoids–acellular pertussis vaccine [DTaP] for children and tetanus-diphtheria, toxoids vaccine for adults [Td] is still used throughout the world for active immunization against diphtheria (Holmes., 2000). Nowadays diphtheria vaccine, require multiple doses to achieve protection, which has led to reduced coverage of immunization, also it may have some side effects in children, such as an allergic reaction (hives or a rash develops within minutes of the injection), seizures or shock — complications, furthermore Toxoids have traditionally been prepared by chemical modification of native toxins (<http://www.cdc.gov/vaccines/vpd-vac/diphtheria/default.htm>) with formaldehyde, for example, the compound is known to be mutagenic and carcinogenic (Turosk, 1985). But molecularly cloned toxin genes now provide alternative genetic approaches to detoxification. Recombinant protein produced technology including the production of proteins which can not be readily purified from natural sources and the development of a small and selected number of amino acid substitutions to detoxify the original proteins, have been thus introduced (Barbieri et al., 1992; Beachey et al., 1981; Fromen-Romano et al., 1997). Besides having the potential to replace classical toxoids, recombinant toxoids could be incorporated by genetic engineering into live attenuated bacterial or viral vaccines currently being developed. Such live vaccines offer the possibility to immunize against a broad array of diseases by administering only a single dose of the vaccine (Killeen et al., 1992). Thus several studies were done for diphtheria toxin activities: Lobeck et al. (1998) combined two fragments of diphtheria toxin (DT), receptor binding

domain and a linear peptide which fused at a tandem repeat of Ig binding domain of protein A called ZZ. They demonstrated that purified complex is well recognized by horse anti-DT antibodies and can bind to Vero cells. But they could not conclude that the complex hybrid constitutes can be an appropriate vaccine against diphtheria. Because first, it remains to be demonstrated that rabbits immunized. Second, their comparative analysis of antisera revealed that the commercial DTx elicits antisera with higher anti-DT titers and higher neutralizing potency compared to substance. Third, Protein A moiety can bind to rabbit IgGs, and the immunization with such a fusion protein may potentially elicit an anti-IgG immune response (Lobeck et al., 1998). Chiang et al. (as reported by Lee et al., 2004), investigated the expression and immunogenicity of a nontoxic DT fragment A (DTA) in *S. gordonii*, with the long-term goal of developing a live oral diphtheria pertussis- tetanus vaccine. They combined DTA with *S.gordonii* major surface antigen P1. The fusion proteins were immunogenic in mice, but the antibodies generated lacked neutralizing activity. The aim of this study was cloning and expression diphtheria toxin gene to produce recombinant protein, as powerful antigen in exciting immuno response, and application in next investigations.

## ACKNOWLEDGMENT

This study was derivative of student thesis and supported by Cellular and Molecular Biology Research Center (CMBRC) of Shaheed Beheshti University of Medical Sciences.

## REFERENCES

- Aybay C, Yücel A (2003). Development of a diagnostic and screening ELISA system for measuring diphtheria anti-toxin levels. *Turk. J. Med. Sci.*, 33: 289-294.
- Bachran C, Sutherland M, Bachran D, Fuchs H (2007). Quantification of diphtheria toxin-mediated ADP-ribosylation in a solid-phase assay. *Clin. Chem.*, 53(9): 1676-1683.
- Baneyx F (1999). Recombinant protein expression in *Escherichia coli*. *Curr. Opin. Biotechnol.*, 10:411-421.
- Barbieri JT, Armellini D, Molkentin J, Rappuoli R (1992). Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin. *Infect. Immun.*, 60: 5071–5077.
- Beachey EH, Seyer JM, Dale JB, Simpson WA, Kang A (1981). Type specific protective immunity evoked by synthetic peptide of *Streptococcus pyogenes* M protein. *Nat.*, 292:457.
- Bigio M, Rossi R, Nucci D, Antoni G, Rappuoli R, Ratti G (1987). Conformational changes in diphtheria toxoids. Analysis with monoclonal antibodies. *FEBS Lett.*, 218: 271–276.
- Brooks GF, Carroll CK, Butel JS, Morse AS (2007). Jawetz, Melnick & Adelberg's Medical Microbiology, edited by G.F. Brooks., 24<sup>th</sup> edition: pp. 154 -217.
- Collier RJ, Kandel J (1971). Structure and activity of diphtheria toxin. I. Thiol-dependent dissociation of a fraction of toxin into enzymatically active and inactive fragments. *J. Biol. Chem.*, 246: 1496-1503.
- DeLange RJ, Drazin RE, Collier RJ (1976). Amino-acid sequence of fragment A, an enzymatically active fragment from diphtheria toxin.

- Proc. Natl. Acad. Sci. U.S.A., 73: 69-72.
- Diphtheria vaccination, Vaccines and preventable diseases: Centers for Disease Control and Prevention. <http://www.cdc.gov/vaccines/vpd-vac/diphtheria/default.htm>
- Drazin R, Kandel J, Collier RJ (1971). Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact molecule. *J. Biol. Chem.*, 246: 1504-1510.
- Felicicello I, Chinali G (1993). A modified alkaline lysis method for the preparation of highly purified plasmid DNA from *E. coli*. *Anal Biochem.*, 212(2): 394 - 401.
- Fromen-Romano C, Maillère B, Drevet P, Lajeunesse E, Ducancel F, Boulain JC, Ménez A (1997). Transformation of a non-enzymatic toxin into a toxoid by genetic engineering. *Protein Eng.*, 10: 101-108.
- Gaastra W, Hansen K (1984). Ligation of DNA with T4 DNA ligase. In *methods in Molecular Biology. Nucleic Acids*. Ed, Walker JM. Humana Press., 2: 225-30.
- Gill DM, Pappenheimer AM Jr (1971). Structure-activity relationships in diphtheria toxin. *J. Biol. Chem.*, 246: 1492-1495.
- Gill DM, Dinius LL (1971). Observations on the structure of diphtheria toxin. *J. Biol. Chem.*, 246: 1485-1491.
- Hanahan D (1983). Studies on transformation on *E. coli* with plasmids. *J. Mol. Biol.*, 166(4): 557-580.
- Holmes RK (2000). Biology and molecular epidemiology of diphtheria toxin and the tox gene. *J. Infect. Dis.*, 181(SUPPL. 1): S156-67
- Honjo T, Nishizuka Y, Hayaishi O (1968). Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis by diphtheria toxin. *J. Biol. Chem.*, 243: 3553-3555
- Hudson L, Hay FC (1998). Antibody interaction with antigen. In: Hudson L, Hay FC. *Practical Immunology*. 3rd ed. Oxford; Boston: Blackwell Scientific Publication., 207 - 263.
- Ittelson TR, Gill DM (1973). Diphtheria toxin: specific competition for cell receptors. *Nature (London)*, 242: 330-332.
- Killeen KP, Escuyer V, Mekalanos JJ, Collier RJ (1992). Reversion of recombinant toxoids: Mutations in diphtheria toxin that partially compensate for active-site deletions. *Proc. Nat. Acad. Sci. USA.*, 89(13): 6207-6209.
- Lobeck K, Drevet P, Léonetti M, Fromen-Romano C, Ducancel F, Lajeunesse E, Lemaire C, Ménez A (1998). Towards a recombinant vaccine against diphtheria toxin. *Infect. Immunity.*, 66(2): 418-423.
- Mandell GBJ, Dolin R (eds.) (1995). *Mandell, Douglas, Bennett's Principles and Practice of Infectious Diseases*. Churchill Livingstone, New York: 1865- 1872.
- Mikhailovich VM, Melnikov VG, Mazurova IK, Wachsmuth IK, Wenger JD, Wharton M, Nakao H, Popovic T (1995). Application of PCR for detection of toxigenic *C. diphtheriae* strains isolated during the Russian diphtheria epidemic, 1990 through 1994. *Clin. J. Microbiol.*, 33(11): 3061-3063.
- Naglich JG, Metherall JE, Russell DW, Eidels L (1992). Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. *Cell*, 69(6): 1051-1061.
- Nakao H, Popovic T (1997). Development of a direct PCR assay for detection of the diphtheria toxin gene. *Clin. J. Microbiol.*, 35(7): 1651-1655.
- Papini E, Rappuoli R, Murgia M, Montecucco C (1993). Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol. *J. Biol. Chem.*, 268(3): 1567-1574.
- Sambrook J, Russell DW (2001). *Molecular cloning. A laboratory manual, cold spring harbor laboratory press, third edition.*, 1,2,3.
- Shewry PR, Fido RJ (1998). Protein blotting, Principles and Applications. In: Rapley R, Walker JM, eds. *Molecular Biomethods Handbook*. Totowa, NJ: Humana Press. pp. 435 - 444.
- Skogen V, Jenum PA, Danilov E, Korolev VN, Halvorsen DS, Sjursen H (2000). Immunity to diphtheria among children in Northern Norway and North- Western Russia. *Vaccine*, 19: 197-203.
- Smith BJ (1984a). Acetic Acid-Urea Polyacrylamide Gel Electrophoresis of Proteins. In: Walker John, ed. *Methods in Molecular Biology. Vol 1*. Clifton: Humana Press, 63 - 73.
- Smith BJ (1984b). SDS polyacrylamide gel electrophoresis of proteins. In: *Methods in Molecular Biology. Vol. 1. Proteins*. Edited by John M Walker., Chap. 6: 41-56.
- Sorensen H, Mortensen K (2005). Advanced genetic strategies for recombinant protein expression in *Escherichia coli*. *J. Biotechnol.*, 115: 113-128.
- Todar K (2008). *Diphtheria*. University of Wisconsin-Madison Department of Bacteriology, pp. 1-8.
- Turosk V (1985). *Formaldehyde: Analytical Chemistry and Toxicology; Advances in Chemistry*. American Chemical Society, Washington DC.
- Uchida T, Pappenheimer AM Jr, Greany R (1973). Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. *J. Biol. Chem.*, 248: 3838-3844.